Suppliers and packagers for generic pharmaceutical drug: FEXOFENADINE HYDROCHLORIDE

FEXOFENADINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	SUSPENSION;ORAL	201373	NDA	Chattem, Inc.	41167-4244-1	1 BOTTLE in 1 CARTON (41167-4244-1) / 240 mL in 1 BOTTLE	2011-03-03
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	SUSPENSION;ORAL	201373	NDA	Chattem, Inc.	41167-4244-4	1 BOTTLE in 1 CARTON (41167-4244-4) / 120 mL in 1 BOTTLE	2011-03-03
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	SUSPENSION;ORAL	201373	NDA	Chattem, Inc.	41167-4244-7	3 BOTTLE in 1 CELLO PACK (41167-4244-7) / 120 mL in 1 BOTTLE	2011-03-03
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	SUSPENSION;ORAL	201373	NDA	Chattem, Inc.	41167-4246-2	1 BOTTLE in 1 CARTON (41167-4246-2) / 240 mL in 1 BOTTLE	2011-03-03
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	SUSPENSION;ORAL	201373	NDA	Chattem, Inc.	41167-4246-4	1 BOTTLE in 1 CARTON (41167-4246-4) / 120 mL in 1 BOTTLE	2011-03-03
Chattem Sanofi	CHILDREN'S ALLEGRA HIVES	fexofenadine hydrochloride	SUSPENSION;ORAL	201373	NDA	Chattem, Inc.	41167-4244-1	1 BOTTLE in 1 CARTON (41167-4244-1) / 240 mL in 1 BOTTLE	2011-03-03
Chattem Sanofi	CHILDREN'S ALLEGRA HIVES	fexofenadine hydrochloride	SUSPENSION;ORAL	201373	NDA	Chattem, Inc.	41167-4244-4	1 BOTTLE in 1 CARTON (41167-4244-4) / 120 mL in 1 BOTTLE	2011-03-03

Fexofenadine Hydrochloride Supply Chain Analysis

Last updated: February 19, 2026

This report details key manufacturers and suppliers of Fexofenadine Hydrochloride (HCl) active pharmaceutical ingredient (API), critical for producing the widely used antihistamine. Analysis focuses on production capacity, regulatory standing, and market positioning.

Who Are the Primary Manufacturers of Fexofenadine HCl API?

The global supply of Fexofenadine HCl API is concentrated among a limited number of manufacturers, primarily located in India and China. These entities possess the large-scale production capabilities and regulatory certifications necessary to serve the global pharmaceutical market.

Key API Manufacturers:

• Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company. They are a significant producer of Fexofenadine HCl, with established manufacturing facilities and a strong regulatory track record.
• Sun Pharmaceutical Industries Ltd.: Another major Indian pharmaceutical company, Sun Pharma is a leading global producer of generic drugs. They are known to manufacture Fexofenadine HCl API at scale.
• Lupin Limited: An Indian multinational pharmaceutical company with a broad portfolio of generic and specialty medicines. Lupin is a supplier of Fexofenadine HCl API.
• Cipla Limited: An Indian multinational pharmaceutical company that manufactures a wide range of pharmaceutical products, including Fexofenadine HCl API.
• Zydus Lifesciences Limited (formerly Cadila Healthcare): An Indian pharmaceutical company with integrated pharmaceutical operations. They are a producer of Fexofenadine HCl API.
• Albemarle Corporation: While Albemarle is a broader specialty chemical company, they have a significant pharmaceutical ingredients division. They have been identified as a supplier of Fexofenadine HCl intermediates and potentially API.
• Divi's Laboratories: An Indian pharmaceutical company specializing in producing intermediates and APIs. Divi's is a significant player in the global API market and is a known producer of Fexofenadine HCl.
• Industria Chimica Emiliana (ICE): An Italian pharmaceutical company that manufactures APIs. ICE is a notable European-based supplier of Fexofenadine HCl.

What is the Regulatory Landscape for Fexofenadine HCl API Suppliers?

Regulatory compliance is paramount for API manufacturers. Key regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, conduct rigorous inspections of manufacturing facilities. Successful inspections and the absence of significant findings are critical for market access.

Key Regulatory Considerations:

• FDA Inspections: Facilities supplying to the U.S. market must undergo FDA inspections. A history of successful inspections and a lack of FDA warning letters or import alerts are indicators of compliance. For instance, a facility with a recent successful FDA inspection in 2023 for its Fexofenadine HCl production line would be considered a reliable supplier for the U.S. market.
• EMA Compliance: Manufacturers supplying to the European Union must comply with EMA guidelines and undergo inspections by national competent authorities within EU member states. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often required for APIs.
• GMP Certification: Good Manufacturing Practices (GMP) are a fundamental requirement. Manufacturers must demonstrate adherence to international GMP standards, which are audited by regulatory agencies and often by customers.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control measures. The acceptance of a DMF by agencies like the FDA indicates a level of scrutiny has been applied.

How is Production Capacity Distributed Geographically?

The majority of Fexofenadine HCl API production capacity is located in Asia, specifically India and China, due to lower manufacturing costs and established pharmaceutical infrastructure. European manufacturers, while fewer in number, offer regional diversification and potentially different supply chain risk profiles.

Geographic Distribution of Capacity:

• India: Dominant global producer, estimated to account for over 50% of global Fexofenadine HCl API manufacturing capacity. This is driven by a mature generic pharmaceutical industry and cost-effective operations.
• China: A significant producer, with several large-scale API manufacturers. Chinese suppliers offer competitive pricing and substantial volume.
• Europe (e.g., Italy): Represents a smaller but important segment of production. European manufacturers often cater to stricter regulatory environments and may offer specialized production capabilities.

What are the Key Quality and Purity Standards for Fexofenadine HCl API?

Fexofenadine HCl API must meet stringent pharmacopeial standards to ensure patient safety and therapeutic efficacy. These standards define acceptable limits for impurities, assay, and other critical quality attributes.

Pharmacopeial Standards:

• United States Pharmacopeia (USP): Specifies assay limits typically between 98.0% and 102.0% on a dried basis. Limits for specific related substances (impurities) are set, for example, Fexofenadine Related Compound A typically at not more than 0.2%.
• European Pharmacopoeia (Ph. Eur.): Similar to USP, Ph. Eur. outlines assay requirements and impurity profiles. The impurity limits are often harmonized with USP to facilitate global trade.
• Japanese Pharmacopoeia (JP): Another key reference standard for quality, ensuring API suitability for the Japanese market.

Manufacturers must consistently demonstrate their ability to produce API within these defined specifications. Analytical testing methods, such as High-Performance Liquid Chromatography (HPLC), are crucial for verifying purity and assay.

What are the Supply Chain Risks Associated with Fexofenadine HCl?

The concentration of manufacturing in specific regions and reliance on a limited number of large-scale producers introduce potential supply chain risks.

Identified Risks:

• Geopolitical Instability: Events in major manufacturing regions (India, China) can disrupt production and logistics.
• Regulatory Changes: New or stricter regulations in manufacturing countries or importing countries can impact supply.
• Raw Material Sourcing: Dependence on specific raw material suppliers for upstream intermediates can create vulnerabilities.
• Natural Disasters and Pandemics: Global events can impact manufacturing operations and transportation networks.
• Quality Control Failures: A significant quality issue at a major supplier can lead to product recalls and market shortages.

Mitigation Strategies:

• Dual Sourcing: Establishing relationships with multiple qualified API suppliers across different geographies.
• Supplier Audits: Conducting regular, in-depth audits of key suppliers to assess their operational resilience and quality systems.
• Inventory Management: Maintaining strategic buffer stocks of API to mitigate short-term disruptions.
• Contractual Agreements: Implementing robust contracts with suppliers that include force majeure clauses and clear performance expectations.

Who are the Major Formulators Using Fexofenadine HCl API?

Numerous pharmaceutical companies worldwide formulate Fexofenadine HCl into finished dosage forms, primarily oral tablets and suspensions. These companies source API from the manufacturers listed above.

Examples of Formulators (Global):

• Sanofi: The originator company of Allegra (Fexofenadine HCl). Sanofi continues to be a significant player through its branded and generic divisions.
• Teva Pharmaceutical Industries: A global leader in generic pharmaceuticals, Teva is a major purchaser and formulator of Fexofenadine HCl.
• Mylan (now Viatris): Another large generic pharmaceutical company with a significant presence in the antihistamine market.
• Hikma Pharmaceuticals: A multinational pharmaceutical company with operations in the U.S., Europe, and the Middle East, supplying various generic medications.
• Apotex: A Canadian pharmaceutical company that manufactures and distributes a wide range of generic drugs globally.

These companies act as the primary demand drivers for Fexofenadine HCl API. Their product portfolios and market strategies directly influence the demand for API from manufacturers.

What is the Projected Market Outlook for Fexofenadine HCl API?

The market for Fexofenadine HCl API is influenced by several factors, including the prevalence of allergic rhinitis and chronic idiopathic urticaria, the expiry of patents, and the growth of generic competition.

Market Dynamics:

• Steady Demand: Fexofenadine HCl is a well-established, non-sedating antihistamine with consistent demand driven by seasonal allergies and year-round allergic conditions.
• Genericization: The compound is off-patent in most major markets, leading to widespread generic availability and intense price competition among formulators, which in turn pressures API pricing.
• Emerging Markets: Growth in emerging economies, as healthcare access expands and disposable incomes rise, is expected to contribute to increased demand for affordable allergy medications.
• Competition from Other Antihistamines: While Fexofenadine HCl holds a strong position, it faces competition from other second-generation antihistamines (e.g., Cetirizine, Loratadine) and newer agents.

The market is characterized by stable, albeit slow, growth. The focus for API manufacturers is on maintaining cost-competitiveness, ensuring high quality, and demonstrating reliable supply to large generic formulators.

Key Takeaways

• The global Fexofenadine HCl API market is dominated by manufacturers in India and China, with significant players including Dr. Reddy's Laboratories, Sun Pharma, and Divi's Laboratories.
• Regulatory compliance, particularly adherence to GMP standards and successful FDA/EMA inspections, is a critical differentiator for API suppliers.
• Geographic concentration of production capacity in Asia presents supply chain risks, necessitating dual sourcing and robust risk management strategies.
• Fexofenadine HCl API must meet stringent USP, Ph. Eur., and JP pharmacopeial standards for assay and impurity profiles.
• The market for Fexofenadine HCl API is mature, driven by steady demand for generic allergy medications, and characterized by price competition.

FAQs

What is the typical lead time for ordering Fexofenadine HCl API from a major supplier?

Typical lead times for Fexofenadine HCl API orders can range from 8 to 16 weeks, depending on the supplier's current production schedule, order volume, and specific quality control requirements. Rush orders may be possible but often incur premium pricing.

How do API manufacturers ensure the traceability of their Fexofenadine HCl batches?

API manufacturers maintain comprehensive batch records that document every step of the manufacturing process, including raw material sourcing, in-process controls, analytical testing, and packaging. These records are essential for full traceability, allowing for recall procedures if necessary.

Are there any specific sustainability initiatives reported by major Fexofenadine HCl API producers?

While specific initiatives vary, leading API manufacturers are increasingly focused on reducing environmental impact through measures such as water conservation, energy efficiency improvements in manufacturing processes, and responsible waste management. Companies often disclose these efforts in their annual sustainability reports.

What are the main quality control tests performed on Fexofenadine HCl API before release?

Key quality control tests include assay (determining the potency of the API, typically via HPLC), identification tests (confirming the identity of the substance), tests for related substances/impurities (identifying and quantifying undesirable compounds), residual solvents, water content, and microbial limits.

How does the pricing of Fexofenadine HCl API compare between Indian and Chinese suppliers versus European suppliers?

Generally, Indian and Chinese suppliers tend to offer more competitive pricing for Fexofenadine HCl API due to lower labor and manufacturing overhead costs. European suppliers, while often fewer in number, may command higher prices due to potentially higher production standards, regional supply chain benefits, and localized regulatory adherence.

Citations

[1] United States Pharmacopeia. (n.d.). Fexofenadine Hydrochloride. USP-NF. Retrieved from [USP-NF website] (Note: Specific monograph access requires subscription) [2] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificates of Suitability (CEP). EDQM Website. Retrieved from [EDQM website] [3] Various Company Annual Reports and Investor Presentations (e.g., Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., Divi's Laboratories). (Accessed 2023-2024). [4] Pharmaceutical Industry Market Research Reports (e.g., Global API Market Analysis, Antihistamines Market Trends). (Data sources vary by report provider). [5] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). FDA Website. Retrieved from [FDA website]